alpha-aminopyridine has been researched along with Skin Neoplasms in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, C; Zhang, W; Zhang, Y; Zhou, DB | 1 |
| Blackham, A; Box, J; Demberger, L; Federowicz, B; Friedland, JC; Ginn, S; Horton, M; Knoerzer, D; McIntosh, A; Nair, S; Shapiro, M; Sheikh, H; Stuhlmiller, TJ; Wolfe, Z | 1 |
| Aasen, SN; Bjerkvig, R; Feng, Z; Hoang, T; Knappskog, S; Parajuli, H; Roy, K; Stokke, K; Thorsen, F; Wang, J | 1 |
| Aplin, AE; Chervoneva, I; Erkes, DA; Field, CO; Rosenbaum, SR; Villanueva, J | 1 |
| Chai, J; Li, M; Li, Z; Liu, X; Mi, J; Qin, H; Wu, J; Xu, J | 1 |
| Afghani, S; Ai, WZ; Balassanian, R; Bandyopadhyay, S; Gao, HX; Gill, R; McCormick, F; Moasser, M; Pincus, L; Rakhshandehroo, T; Rubenstein, J; Wang, L; Wu, CH; Yang, CY | 1 |
| Brotherton, R; Chang, ALS; Moffat, A; Pague, A; Tran, DC; Zhu, GA | 1 |
| Aptullahoglu, E; Esfandiari, A; Ho, YH; Lovat, P; Lunec, J; Mahdi, AK; Wang, N; Wu, CE | 1 |
| Chen, J; Cheng, C; He, MX; Yang, D; Yang, JM; Zhang, WP | 1 |
| Che, Y; Ding, X; Song, J; Sun, X; Xu, L; Zhang, X | 1 |
| Wang, Q; Weisberg, E; Zhao, JJ | 1 |
| Blank, C; Cornelissen-Steijger, PD; Geukes Foppen, MH; Goding, CR; Graeber, TG; Haanen, J; Hugo, W; Kemper, K; Kong, X; Krijgsman, O; Lo, RS; McDermott, U; Müller, J; Peeper, DS; Possik, PA; Ribas, A; Robert, L; Song, C; Tsoi, J | 1 |
| Dong, M; Fan, Y; Feng, J; Hong, X; Huang, H; Ke, X; Li, W; Lu, X; Ning, Z; Qi, J; Shen, Z; Shi, Y; Yu, L; Zhang, W; Zhao, X; Zhou, D; Zhu, J | 1 |
| Miele, L; Morello, S; Pinto, A; Porta, A; Sorrentino, C | 1 |
| Anderton, SM; Brunton, VG; Byron, A; Canel, M; Frame, MC; Gilbert, N; Gómez-Cuadrado, L; Lund, T; Maniati, E; McPherson, RC; Muir, M; Nibbs, RJ; Pachter, JA; Ring, JE; Serrels, A; Serrels, B; Sims, AH; von Kriegsheim, A | 1 |
| Geisslinger, G; King-Himmelreich, TS; Laarmann, K; Meissner, M; Möser, CV; Niederberger, E; Olbrich, K; Wolters, MC | 1 |
1 trial(s) available for alpha-aminopyridine and Skin Neoplasms
| Article | Year |
|---|---|
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Benzamides; Disease-Free Survival; Enteropathy-Associated T-Cell Lymphoma; Female; Histone Deacetylase Inhibitors; Humans; Leukopenia; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Mycosis Fungoides; Neoplasm Recurrence, Local; Neutropenia; Skin Neoplasms; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
15 other study(ies) available for alpha-aminopyridine and Skin Neoplasms
| Article | Year |
|---|---|
[Long-term remission of a patient with Sézary syndrome treated with chidamide combined with PD-1 blockade: a case report].
Topics: Aminopyridines; Benzamides; Humans; Programmed Cell Death 1 Receptor; Sezary Syndrome; Skin Neoplasms | 2022 |
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.
Topics: Aminopyridines; Cell Line, Tumor; Humans; MAP Kinase Signaling System; Melanoma; Melanoma, Cutaneous Malignant; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrroles; Skin Neoplasms | 2022 |
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Melanoma; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction; Skin Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Cell Proliferation; Macrophages; Male; Melanoma; Mice, Inbred C57BL; Proteins; Proto-Oncogene Proteins B-raf; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Skin Neoplasms; Treatment Outcome | 2020 |
E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hydroxyquinolines; Melanoma; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, IGF Type 1; Skin; Skin Neoplasms | 2020 |
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Female; Gene Knockdown Techniques; High-Throughput Screening Assays; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lymphoma, T-Cell, Cutaneous; Mice; Morpholines; Protein Kinase Inhibitors; Skin; Skin Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Carcinoma, Basal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Prospective Studies; Pyridines; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Topics: Aminopyridines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dipeptides; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Melanoma, Cutaneous Malignant; Mutagenesis, Site-Directed; para-Aminobenzoates; Phosphorylation; Piperazines; Protein Binding; Protein Phosphatase 2C; Protein Stability; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Skin Neoplasms; Tumor Suppressor Protein p53 | 2018 |
Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report.
Topics: Aminopyridines; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Skin Neoplasms; Stomach Neoplasms | 2018 |
Effective remission of chidamide on treatment of advanced mycosis fungoides: An unusual case report.
Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Cyclophosphamide; Etoposide; Female; Humans; Mycosis Fungoides; Quality of Life; Skin Neoplasms; Treatment Outcome; Vincristine | 2019 |
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
Topics: Alleles; Aminopyridines; Animals; Breast Neoplasms; Class Ia Phosphatidylinositol 3-Kinase; Disease Models, Animal; Female; Gene Dosage; Genotype; Hamartoma Syndrome, Multiple; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Skin Neoplasms | 2013 |
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Imidazoles; Indoles; Melanoma; Mice; Microphthalmia-Associated Transcription Factor; Oximes; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Receptor Protein-Tyrosine Kinases; Signal Transduction; Skin Neoplasms; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2014 |
Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model.
Topics: Aminopyridines; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Antigens, Ly; CD11b Antigen; Disease Models, Animal; Female; Flow Cytometry; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Myeloid Cells; Neovascularization, Pathologic; Receptor, Adenosine A2B; Skin Neoplasms; T-Lymphocytes; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2015 |
Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.
Topics: Aminopyridines; Animals; Carcinoma, Squamous Cell; Chemokine CCL5; Disease Models, Animal; Focal Adhesion Protein-Tyrosine Kinases; Humans; Keratinocytes; Mice; Mice, Nude; Skin Neoplasms; T-Lymphocytes, Regulatory; Transcription, Genetic; Tumor Escape | 2015 |
The protein kinase IKKepsilon contributes to tumour growth and tumour pain in a melanoma model.
Topics: Aminopyridines; Animals; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; I-kappa B Kinase; Melanocytes; Melanoma; Melanoma, Experimental; Mice, Inbred C57BL; Mice, Knockout; Pain; Skin Neoplasms | 2016 |